An Observational Study of Tarceva (Erlotinib) in First Line in Patients With Advanced EGFR Mutation-Positive Non-Small Cell Lung Cancer (GERTAC)

NCT01790217 · clinicaltrials.gov ↗

COMPLETED

Status

52

Enrollment

INDUSTRY

Sponsor class

Conditions

Non-Squamous Non-Small Cell Lung Cancer

Sponsor

Hoffmann-La Roche